[Revised January 21, 2026]

HCP Data Providers

The U.S. life sciences market relies on numerous specialized vendors for Healthcare Professional (HCP) data. Major commercial providers include:

• IQVIA (OneKey) – A legacy of IMS Health, IQVIA's OneKey database now covers over 25 million HCPs and more than 6 million HCOs across 118 countries, including approximately 1.2M U.S. physicians across 248 specialties (^[1]). The platform delivers over 250 attributes per profile and receives more than 1.5 million updates globally each month, with a 2025 random demographic audit showing 99%+ data accuracy. OneKey is ISO 9001 certified and audited by the Alliance for Audited Media, reflecting its quality emphasis (^[2]) (^[1]). IQVIA also offers prescription/dispensing datasets (e.g. Xponent and LRx), covering ~90–93% of U.S. retail pharmacy claims for prescriber-level analysis (^[3]). For FY2025, IQVIA raised full-year revenue guidance to $16.0–16.4 billion.
• Definitive Healthcare – A publicly traded analytics firm (Nasdaq: DH), with over 3 million U.S. HCP profiles and more than 310,000 healthcare organizations (^[4]). Its data include clinician demographics (NPI, name, specialties, affiliations, practice address), business contact info (email, phone) and extensive claims/prescribing records (nearly 28 billion annual Rx claims) (^[4]) (^[5]). Definitive updates in real time and claims to be one of the few vendors linking 28B Rx and 12.5B medical claims to identifiable providers (^[6]). For FY2025, Definitive Healthcare projects revenue of $237–240 million, with strong enterprise customer growth and improved retention (^[7]).
• Veeva Systems (OpenData) – A major CRM/MDM vendor for pharma. Veeva’s OpenData Network contains ~12 million global healthcare records (HCPs and HCOs), with detailed fields (names, business addresses, emails, phone numbers, specialty, license/DEA numbers, affiliations, and compliance flags). It integrates with Veeva CRM and Vault for pharma marketing. (Veeva reached $2.747 billion in revenue for FY2025 (year ended Jan 31, 2025) and projects $3.17 billion for FY2026, with over 300 customers having selected OpenData (^[8]).)
• LexisNexis Health Care (Enclarity) – Builds HCP profiles by linking professional licensure, legal and financial records. Its data set can include ~125 fields per provider, combining claims and licensing data with consumer credit/financial attributes (^[9]). LexisNexis attaches a confidence score to each profile to indicate completeness (^[9]). (Note: LexisNexis acquired Health Market Science and Cegedim’s data units.)
• MedPro Systems – A provider of verified contact and license data for HCPs. MedPro aggregates from 800+ state regulatory sources (^[10]) to deliver comprehensive profiles. Its records contain up to 300 data fields per provider (^[11]) (address, email, phone, license status, sanctions, affiliations, etc.). MedPro specializes in license verification and sanctions screening under laws like DQSA (^[11]).
• AMA Physician Masterfile – The American Medical Association maintains a registry of licensed U.S. physicians. It covers over 1.4 million current and historical MD/DO records (names, specialty, practice locations, education/training) (^[12]). Pharma firms often license AMA Masterfile snapshots as a baseline contact list (though it may lack some direct emails or mobile numbers).
• H1 (H1Insights) – A rapidly growing data platform aggregating global HCP information. H1 serves over 250 companies and claims profiles on 11+ million providers worldwide (^[13]), including doctors' specialties, institutional affiliations, publication and clinical trial records, and peer network data. In June 2025, H1 acquired Veda Data Solutions to create the industry's first comprehensive end-to-end provider data platform integrating provider directories, networks, rosters, and credentialing (^[14]). H1 is backed by investors including Altimeter, Goldman Sachs Asset Management, and is ranked among Y Combinator's Top Private Companies.
• AcuityMD – A surgical/medical device intelligence provider named to Forbes' 2025 "Next Billion-Dollar Startups" list. Its U.S. dataset focuses on clinicians (especially surgeons) and facilities, with procedure volumes, referral networks, payer mixes and affiliations. AcuityMD now serves 300+ MedTech customers—including six of the top 10—such as Becton Dickinson, Teleflex, and Olympus (^[15]). The company has raised over $83 million in funding and expanded its AI platform in October 2025 to further automate data management and sales activity (^[16]).
• MedTechIntel, MedScout, MedicoReach – Specialized healthcare data vendors. For example, MedTechIntel (musculoskeletal focus) lists ~90K+ surgeons, ASCs and distributors (^[17]). MedScout offers HCP, patient and referral data (including prescription and payment trends) (^[18]). MedicoReach aggregates 8+ million global HCP/HCO contacts (physicians, dentists, nurses, etc.) with 90%+ email accuracy (^[19]). These niche vendors often target device and biotech marketing needs with tailored analytics.

In addition to private vendors, public sources exist. For example, the U.S. NPI Registry (CMS) is a free database of all covered providers’ identifiers, practice addresses and taxonomy codes (currently several million NPIs active (^[20])). State medical licensing boards and hospital directories also supply partial data. Many vendors (MedPro, Definitive, etc.) incorporate these public records into their proprietary files.

U.S. Laws and Regulations Governing HCP Data

Legal requirements in the U.S. cover various aspects of HCP data use. Key rules include:

• HIPAA Privacy Rule – Primarily protects patients’ health information, not providers’ business data. In general, pure HCP contact data (name, business address, specialty) is not PHI. However, HIPAA does affect any marketing that uses patient health data. For example, targeted outreach based on patient health records (or sharing PHI in testimonials) must follow HIPAA authorization rules (^[23]). In practice, pharma marketing teams avoid using identifiable patient records without consent. Any HCP data derived from healthcare transactions (e.g. prescribing patterns linked to patient claims) must be de-identified or handled by business associates under HIPAA compliance. 2026 Update: A major proposed HIPAA Security Rule overhaul (published January 2025) remains on track for finalization in May 2026, introducing mandatory multi-factor authentication, encryption standards for ePHI, and faster breach reporting requirements (^[24]).
• CAN-SPAM Act (2003) – Governs all commercial email in the U.S. Any marketing email to HCPs must identify the sender clearly, use accurate headers/subject lines, and include a conspicuous “unsubscribe” option (^[25]). Misleading or deceptive content is prohibited, and opt-out requests must be honored promptly (^[25]). For example, an email blast to physicians must allow recipients to easily decline further mail (and must not use false “reply” addresses).
• TCPA (Telephone Consumer Protection Act, 1991) – Limits telemarketing calls and texts. It prohibits using an automatic telephone dialing system or prerecorded voice to call or text cell phones without the recipient's prior consent (^[26]). 2025 Update: The FCC's "one-to-one consent" rule, which would have required consent be limited to a single specific seller, was vacated by the U.S. Court of Appeals (Eleventh Circuit) in January 2025 and formally eliminated by FCC final rule in September 2025 (^[27]). However, the TCPA's new "Opt-Out Rule" took effect on April 11, 2025, making it easier for consumers to revoke consent to receive robocalls and robotexts. Note that CMS still requires one-to-one consent for Medicare marketing outreach. In practice, pharma companies must document any consent (often written) before auto-dialing a physician's mobile. Cold-calling or texting HCPs' cell phones without express permission can incur statutory damages of $500–1,500 per violation.
• Physician Payments Sunshine Act – Part of the ACA (implemented 2013), it requires manufacturers of drugs, devices or biologics to track and report almost all payments or transfers of value to U.S. physicians and teaching hospitals. CMS publishes this data annually on the Open Payments website. The Program Year 2024 data (published July 2025) includes 16.16 million records totaling $13.18 billion in payments to covered recipients, with detailed data from 2018–2024 available on the Open Payments Search Tool (^[28]). Pharma companies must maintain auditable records of consulting fees, research grants, speaker honoraria, meals, travel and other transfers to HCPs, so that they can be reported accurately and reviewed by the HCPs.
• State Privacy Laws (e.g. CCPA/CPRA) – Broad consumer privacy laws now exist in 19 states as of January 2026, with Kentucky, Indiana, and Rhode Island joining the list on January 1, 2026 (^[29]). California's CCPA/CPRA (effective 2020/2023) gives Californians the right to know, delete, and opt-out of "sale" or sharing of their personal information, with CPRA adding regulations for automated decision-making and risk assessments effective January 2026 (^[30]). Although these laws exempt medical PHI held by HIPAA-covered entities (^[31]), they generally apply to non-HIPAA personal data. State enforcement is accelerating—in July 2025, California secured its largest CCPA settlement to date ($1.55 million), and Texas has secured settlements exceeding $1 billion under its state privacy act. For example, a California-licensed physician could request deletion of a personal email address from a vendor's database under CCPA.

These laws operate alongside industry codes of conduct (e.g. the AdvaMed or PhRMA Codes) and FDA/FTC advertising rules. All promotional and data practices must comply with anti-kickback statutes and truthful marketing requirements as well.

Compliance Requirements (Pharma/IT) with Examples

Pharmaceutical companies and their IT teams must translate these laws into concrete practices. Key compliance steps include:

• Email Marketing Compliance: Always honor CAN-SPAM opt-outs. For example, every promotional email to HCPs should contain a clear unsubscribe link and truthful sender information (^[25]). Marketers must never use misleading subject lines. E-mail tracking should flag any bounce or opt-out to remove that physician from future lists.
• Telephone/Texting Rules: Before calling or texting providers on mobile phones, confirm prior express consent as required by TCPA (^[32]). Maintain a do-not-call list for HCPs who have opted out. For any automated outreach (e.g. appointment reminders, product updates), ensure the dialer system is compliant and records consent documents. Failing to vet a physician’s number (e.g. dialing reassigned personal numbers) can lead to violations (^[33]).
• HIPAA/Privacy Safeguards: Ensure no protected patient data is used in HCP campaigns. For instance, if a sales CRM holds de-identified prescribing data, it must remain unlinked to patient identities. IT systems should encrypt any PHI and enforce role-based access controls (HIPAA requires minimum necessary use). Any health data used for targeting must be fully de-identified or used under business-associate agreements (^[23]).
• Sunshine Act Recordkeeping: Track all transfers of value to HCPs with precision. Systems must record the HCP’s legal name, NPI, affiliated institution and payment details. Before reporting, manufacturers must allow physicians to review and dispute the data. For example, if a rep provides a physician with an iPad for presentations, IT should ensure that expense is captured and coded correctly so it shows up in the physician’s Open Payments record.
• CCPA/State-Law Compliance: If handling HCPs’ personal data (especially of residents in regulated states), update privacy policies accordingly. Provide mechanisms for physicians to exercise rights – e.g. a public “Do Not Sell My Info” notice, and procedures to locate and delete a provider’s personal info on request (^[34]). Log data processing activities and obtain consents where needed for analytics or data enrichment.
• Consent & Preference Management: Implement explicit consent tracking for outreach. For example, use MDM tools (like Veeva Network) to flag each HCP’s communication preferences. The Align Biopharma consortium (led by Veeva) is developing a standard so HCPs can specify which communications they accept (^[35]). Even today, pharma IT should store opt-in/opt-out flags (e.g. physician registered/not registered for email campaigns) and respect them across systems.

Taken together, these requirements mean that IT systems must combine data governance with compliance logic. For example, customer master data applications should enforce validation rules (no adult patient PHI fields in provider profiles) and filter out any non-business addresses. In marketing automation, transactional data flows should include consent checks and suppression lists. Audit trails are critical: every use of HCP data should be logged so that compliance officers can demonstrate adherence (e.g. which email blasts went to which physicians and when they opted out).

Market Size and Industry Statistics

The market for HCP data and analytics is significant and growing. Industry reports estimate the global healthcare provider data management software market was about $3.2 billion in 2024, projected to reach ~$6.5 billion by 2033 (^[36]). This includes MDM, CRM and analytics solutions that underpin HCP data. In the U.S., major companies’ financials illustrate the scale: IQVIA reported $16.0–16.4 billion in revenue for FY2025 (^[37]), and Veeva Systems reached $2.747 billion in FY2025, with Q3 FY2026 revenue of $811.2 million (up 16% YoY) (^[38]). By comparison, Definitive Healthcare’s 2024 revenue was $252 million (^[39]), reflecting its niche focus.

As context for data volumes: a CDC analysis notes the AMA Masterfile contains 1.4 million active physicians and residents in the U.S. (^[12]). Definitive Healthcare alone profiles over 3 million U.S. providers and 310,000+ healthcare organizations (^[4]). Veeva’s network spans 12+ million HCP/HCO global records, and H1 aggregates ~11 million worldwide (^[22]). Meanwhile, the CMS Open Payments database published 16.16 million payment records totaling $13.18 billion for Program Year 2024 alone (data from 2018–2024 is available on the Open Payments Search Tool), underscoring the volume of pharma–HCP financial interactions.

In summary, the HCP data solutions sector (provider directories, prescribing databases, CRM/MDM platforms) represents a multibillion-dollar industry. The U.S. life sciences field continually invests in these tools – for example, IQVIA’s R&D/analytics business grew 6% in 2023 (^[37]) – reflecting the strategic value of accurate provider information.

Best Practices and Data Governance in Pharma IT

To ensure compliance and ethical use of HCP data, IT departments in pharma companies should adopt robust data governance and security practices:

• Data Classification & Minimization: Define data categories (e.g. “business contact,” “licensure data,” “sensitive personal”) and only collect fields needed for a purpose. Avoid storing non-work personal identifiers (like home addresses) when possible. This limits exposure under privacy laws. Keep an inventory (data map) of all HCP information sources and flows.
• Strong Access Controls: Implement role-based access and multi-factor authentication for all HCP databases (^[40]). For example, marketing teams might see only business contact info, while legal/compliance roles can access payment records. Regularly review permissions (e.g. employee/partner offboarding).
• Encryption and Security: Encrypt HCP data at rest and in transit (^[40]) (^[41]). Use VPNs or secure APIs for data sharing. If a breach occurs, encryption ensures intercepted records remain unintelligible. Patch and harden servers storing sensitive data.
• Data Quality & Master Data Management: Use MDM systems (e.g. Veeva Network, Reltio) to deduplicate and unify HCP identities. Regularly cleanse lists against up-to-date sources (e.g. NPI updates, state board feeds). High-quality data helps compliance (e.g. sending emails to valid addresses avoids spam issues) and analytics accuracy.
• Audit Logging & Monitoring: Maintain detailed logs of data access and transactions. Real-time monitoring or anomaly detection platforms can alert on unusual activity (e.g. bulk downloads) (^[42]). Conduct periodic audits of data usage, permissions, and third-party vendor compliance. For example, verify that a mailing list vendor is not including opted-out HCPs.
• Consent and Preference Tracking: As noted above, record each HCP’s communication preferences (^[35]). For instance, if a doctor declines email marketing, flag their record so all systems honor that choice. Embed consent options in digital signup forms (e.g. allow HCPs to select topics of interest). This not only aids TCPA/CAN-SPAM compliance, but also aligns with ethical marketing.
• Governance Policies and Training: Develop written policies covering HCP data handling (e.g. “No PHI in Marketing Collateral”). Train sales, marketing and IT staff on these policies and relevant laws. For example, ensure reps know not to capture patient stories without HIPAA-compliant approvals. Review and update policies when regulations change.
• Vendor Due Diligence: When licensing HCP lists or analytics from third parties, require contractual assurances of legal sourcing and data accuracy. Evaluate vendors’ privacy/security certifications. For instance, if a vendor claims to use “publicly scraped” email addresses, confirm that this complies with data protection rules.

By combining these practices, pharma IT can build a compliant, secure infrastructure for HCP data. For example, a best-in-class approach might use a data governance platform that automates data quality checks and lineage tracking, while business rules enforce that any outbound marketing contact list is pre-screened against opt-out flags (^[43]) (^[42]). Ongoing review and cross-functional oversight (including legal, medical affairs, IT and marketing) ensure that HCP data drives business value safely and in accordance with U.S. law.

Sources: Authoritative industry and government publications (e.g. IQVIA and Definitive earnings reports (^[37]) (^[39]), CMS/CDC statistics (^[12]) (^[44]), verified market research (^[36]), and compliance guides (^[25]) (^[32])) were used to compile this report. Each provider and legal requirement is cited to credible sources as noted.